Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28599
Title: | Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. | Austin Authors: | Phetsouphanh, Chansavath;Darley, David R;Wilson, Daniel B;Howe, Annett;Munier, C Mee Ling;Patel, Sheila K ;Juno, Jennifer A;Burrell, Louise M ;Kent, Stephen J;Dore, Gregory J;Kelleher, Anthony D;Matthews, Gail V | Affiliation: | Medicine (University of Melbourne) Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School, Monash University, Melbourne, Victoria, Australia The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia St Vincent's Hospital, Darlinghurst, New South Wales, Australia Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia Department of Mathematics and Statistics, Boston University, Boston, MA, USA |
Issue Date: | Feb-2022 | Date: | 2022-01-13 | Publication information: | Nature Immunology 2022; 23(2): 210-216 | Abstract: | A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to age- and gender-matched recovered individuals without LC, unexposed donors and individuals infected with other coronaviruses. Patients with LC had highly activated innate immune cells, lacked naive T and B cells and showed elevated expression of type I IFN (IFN-β) and type III IFN (IFN-λ1) that remained persistently high at 8 months after infection. Using a log-linear classification model, we defined an optimal set of analytes that had the strongest association with LC among the 28 analytes measured. Combinations of the inflammatory mediators IFN-β, PTX3, IFN-γ, IFN-λ2/3 and IL-6 associated with LC with 78.5-81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/28599 | DOI: | 10.1038/s41590-021-01113-x | ORCID: | http://orcid.org/0000-0001-6617-5995 http://orcid.org/0000-0002-9721-101X http://orcid.org/0000-0002-6419-142X http://orcid.org/0000-0002-9072-1017 http://orcid.org/0000-0003-1863-7539 http://orcid.org/0000-0002-8539-4891 http://orcid.org/0000-0002-0009-3337 http://orcid.org/0000-0002-0626-1899 |
Journal: | Nature Immunology | PubMed URL: | 35027728 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35027728/ | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.